These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10546795)

  • 1. Minimal residual disease.
    Lion T
    Curr Opin Hematol; 1999 Nov; 6(6):406-11. PubMed ID: 10546795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease: relevance for diagnosis and treatment of human malignancies.
    Hirsch-Ginsberg C
    Annu Rev Med; 1998; 49():111-22. PubMed ID: 9509253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease testing in hematologic malignancies and solid cancer.
    Ben Lassoued A; Nivaggioni V; Gabert J
    Expert Rev Mol Diagn; 2014 Jul; 14(6):699-712. PubMed ID: 24938122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Donor chimerism and minimal residual disease monitoring in leukemia patients after allo-HSCT].
    Bogdanov KV; Motorin DV; Nikulina TS; Pisotskaya OS; Babenetskaya DV; Mirolyubova YV; Volkova OY; Zaritskiy AY
    Biomed Khim; 2017 Nov; 63(6):570-581. PubMed ID: 29251621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multiparametric scanning system for evaluation of minimal residual disease in hematological malignancies.
    Trakhtenbrot L; Rechavi G; Amariglio N
    Acta Haematol; 2004; 112(1-2):24-9. PubMed ID: 15179001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow Cytometric Assessment of Malignant Hematologic Disorders.
    Hartzell CM; Shaver AC; Mason EF
    Clin Lab Med; 2024 Sep; 44(3):465-477. PubMed ID: 39089752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotyping of leukemia.
    Campana D; Behm FG
    J Immunol Methods; 2000 Sep; 243(1-2):59-75. PubMed ID: 10986407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning.
    Shimoni A; Nagler A
    Acta Haematol; 2004; 112(1-2):93-104. PubMed ID: 15179009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.
    Meirow D; Hardan I; Dor J; Fridman E; Elizur S; Ra'anani H; Slyusarevsky E; Amariglio N; Schiff E; Rechavi G; Nagler A; Ben Yehuda D
    Hum Reprod; 2008 May; 23(5):1007-13. PubMed ID: 18344563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of minimal residual disease in stem cell grafts and the role of purging: is it better to purge in vivo or in vitro?
    Melillo L; Cascavilla N; Lerma E; Corsetti MT; Carella AM
    Acta Haematol; 2005; 114(4):206-13. PubMed ID: 16269860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the detection of minimal residual disease.
    Radich J; Thomson B
    Curr Opin Hematol; 1997 Jul; 4(4):242-7. PubMed ID: 9260051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease: detection, clinical relevance, and treatment strategies.
    Dwenger A; Lindemann A; Mertelsmann R
    J Hematother; 1996 Oct; 5(5):537-48. PubMed ID: 8938526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.
    Nyvold CG
    Expert Rev Mol Diagn; 2015 May; 15(5):581-4. PubMed ID: 25676837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease in multiple myeloma: use of magnetic resonance imaging.
    Hillengass J; Merz M; Delorme S
    Semin Hematol; 2018 Jan; 55(1):19-21. PubMed ID: 29759148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results.
    Campana D
    Int J Clin Lab Res; 1994; 24(3):132-8. PubMed ID: 7819592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
    Kröger N; Bacher U; Bader P; Böttcher S; Borowitz MJ; Dreger P; Khouri I; Olavarria E; Radich J; Stock W; Vose JM; Weisdorf D; Willasch A; Giralt S; Bishop MR; Wayne AS
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1325-46. PubMed ID: 20637879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence in situ hybridization panel for monitoring of minimal residual disease in patients with double minute chromosomes.
    Jeon Y; Kim SY; Kim M; Park HK; Lee SH; See CJ; Kwon J; Lee DS
    Blood Cells Mol Dis; 2014 Apr; 52(4):208-13. PubMed ID: 24211232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterisation of minimal residual disease in solid tumors.
    Pantel K; Otte M
    Acta Med Austriaca Suppl; 2000; 52():8-12. PubMed ID: 11261279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.